Abstract 97P
Background
The search for genetic markers of prognosis seems promising for individualization of treatment programs for patients with brain tumors. The aim of our study is to study the dynamics of the concentration of mutant DNA in the BRAF gene in peripheral blood plasma during and after radiation therapy and compare these data with the effect of treatment.
Methods
Digital droplet PCR (ddPCR) was used to determine the concentration of mutant tumor DNA in 209 blood plasma samples (groups included 57 patients with pons tumors and 29 patients with glioma of the other localization). The samples were obtained before the course of RT, during RT (5-8 fraction) and after RT (27-30 fraction). According to the results of radiation therapy, patients were divided into two groups: 1 – the onset of tumor recurrence less than 6 months after the end of the course of RT; 2 – stabilization of the process for 6 months or more after the end of the course of RT.
Results
A significant increase in the relative concentration of mutant (V600E) DNA of the BRAF gene in peripheral blood at the beginning of the RT course and its decrease by the end of the course in the relapse-free group was shown. No changes or an increase in BRAFV600E levels by the end of the RT course was typical for patients with relapse in the early stages.
Conclusions
Methods of liquid biopsy allow to estimate changes in the amount of mutant (tumor) DNA in peripheral blood plasma in children with brain glioma in RT. Increase in the level of mutant DNA correlates with a more stable effect of the treatment.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Federal State Budgetary Institution Russian Scientific Center of Roentgenoradiology (RSCRR) of the Ministry of Healthcare of the Russian Federation (Russian Scientific Center of Roentgenoradiology).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Functional characterization of the novel long intergenic non-coding RNA-RFC4, a transcript regulating chromosomal instability in prostate cancer
Presenter: Rogelio Montiel Manríquez
Session: Cocktail & Poster Display session
Resources:
Abstract
52P - The concentration of mutated copies of driver genes in plasma closely mirrors the disease course in colorectal cancer, lung cancer, and melanoma patients
Presenter: Ekaterina Kuligina
Session: Cocktail & Poster Display session
Resources:
Abstract
53P - Heterogeneous characteristics of KRAS mutation subtypes in surgically resected lung adenocarcinomas
Presenter: Kazuya Takamochi
Session: Cocktail & Poster Display session
Resources:
Abstract
54P - ATRX-deficient IDH-wildtype adult high-grade gliomas display novel, clinically relevant genetic patterns by comprehensive genomic profiling
Presenter: Gábor Bedics
Session: Cocktail & Poster Display session
Resources:
Abstract
55P - EGFR variant allele frequency (VAF) impacts on metastatic NSCLC patients outcome during first-line osimertinib
Presenter: Silvia Teresa Riva
Session: Cocktail & Poster Display session
Resources:
Abstract
57P - Clinical characteristics and outcomes in non-small cell lung cancer (NSCLC) with tumour and germline BRCA1/2 mutations
Presenter: Greydon Arthur
Session: Cocktail & Poster Display session
Resources:
Abstract
58P - Molecular investigation using microarray-based comparative genomic hybridization in patients with myelodysplastic syndrome and normal karyotype
Presenter: Mohamed abd naceur AMMAR
Session: Cocktail & Poster Display session
Resources:
Abstract
59P - Unraveling methylation signatures in RAS/BRAF wild-type colorectal cancer patients to identify predictive biomarkers for anti-epidermal growth factor receptor therapy
Presenter: Ana Regina de Abreu
Session: Cocktail & Poster Display session
Resources:
Abstract
60P - Spindle cell sarcomas with tyrosine kinase rearrangement
Presenter: Lenka Krsková
Session: Cocktail & Poster Display session
Resources:
Abstract
61P - Deconvoluting the intra-tumour heterogeneity and subclonal evolution of CDK4/6 inhibitor resistance in ER+ breast cancer
Presenter: Ioanna Mavrommatis
Session: Cocktail & Poster Display session
Resources:
Abstract